Christopher A. Kroeger, M.D.
President and Chief Executive Officer
Dr. Kroeger was appointed President and Chief Executive Officer in 2008, having served on the company's Board of Directors since 2006. He brings a unique combination of commercial, clinical, scientific and entrepreneurial finance expertise to Cardioxyl. Prior to joining the company, Dr. Kroeger led the biopharmaceutical and medical device investing efforts for the Aurora Funds, where he was involved in the board governance and/or strategic oversight of over a dozen venture backed drug and medical device companies. He currently sits on the boards of CardioFocus, Hyperbranch Medical Technologies, Neotropix and Paringenix. Previously, Dr. Kroeger trained in General Surgery at Brigham and Women's Hospital in Boston. Dr. Kroeger earned his MBA from Harvard Business School, his M.D. from Stanford University School of Medicine, and his BS from Harvard University.